For the third consecutive year, the Alliance convened a panel at the 2026 J.P. Morgan Healthcare Conference (JPM) in San Francisco, followed by an Alliance side meeting held at Accenture’s San Francisco Innovation Hub. This year’s panel brought together leaders from Gilead Sciences, U.S. Development Finance Corporation (DFC), Nivi, Inc., reach52, and Accenture to explore how pharmaceutical partnerships, development finance, and patient platforms are creating investable infrastructure in high-growth markets across Asia and Africa. The panel underscored that the most promising long-term opportunities in emerging markets lie not just in individual products, but in the systems and partnerships that connect them to patients.

On September 9, the Alliance hosted AI-Assisted Ultrasound: Bridging Innovation and Access in Low-Resource Settings as part of our 2025 AI and Global Health Discussion Series, sponsored by Pfizer. The panel brought together multi-sector perspectives from AMPATH Kenya, the Gates Foundation, the Global Ultrasound Institute (GUSI), Philips Ultrasound, and UCSF’s Bixby Center for Global Reproductive Health. Together, the expert panelists explored how AI-assisted ultrasound can transform care in low-resource settings while addressing the challenges of implementation.

Check out our AI and global health landing page for more on AI and Health.

At a pivotal moment for global health, the Bay Area Global Health Alliance’s 2025 Annual Meeting convened a diverse community of leaders, innovators, funders, and implementers to confront urgent challenges and chart what’s next. Held under Chatham House Rules to encourage open dialogue, the convening underscored implications for the sector amid deep funding cuts — yet speakers and members alike called for bold action and new ways to collaborate, fund, and lead.

The white paper, Generative AI for Health in LMICs, examines how GenAI is being used in global health and what is needed to maximize its impact. Conducted by the Stanford Center for Digital Health in collaboration with the Alliance and with support from AHO, the research draws on expert insights from roundtables, interviews, surveys, and an analysis of 14 GenAI accelerator programs. On March 26, the Alliance hosted the virtual launch event of the white paper, exploring the top 5 key findings of the report.

Check out our AI and global health landing page for more on AI and health, with thanks to Pfizer for its support of our AI and Global Health Discussion Series.